Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
Diagn Mol Pathol
; 16(4): 207-10, 2007 Dec.
Article
in En
| MEDLINE
| ID: mdl-18043283
ABSTRACT
The demand for both reflexed and primary fluorescence in-situ hybridization (FISH) testing in the clinical setting is increasing. Relevant literature has reported the incidence of HER2 overexpression in 20% to 30% of cases, but some reports suggest that HER2 gene amplification rates are substantially lower. Published data, however, on primary FISH assessment from a single institution is limited, especially information about the frequency of the anomalous genotypes defined by FISH. We report our experience with primary FISH testing in 742 consecutive cases of breast cancer, in the calendar year 2006. Eighty percent (595/742) of the breast cancer cases were not amplified for HER2 (HER2/CEP17=0.8-1.9), whereas 19% (142/742) of cases were HER2 amplified (HER2/CEP17>or=2.0). Among the HER2-amplified cases, 3% (19/742) were low-level amplified (HER2/CEP17 ratio=2.0-2.5). Genotypic heterogeneity, defined as >5% but <50% of the tumor cells demonstrating HER2 gene amplification, was observed in 5% (40/7242) of the cases. HER2 monoallelic deletion (HER2/CEP17
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Adenocarcinoma
/
In Situ Hybridization, Fluorescence
/
Receptor, ErbB-2
Type of study:
Evaluation_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Diagn Mol Pathol
Journal subject:
BIOLOGIA MOLECULAR
/
PATOLOGIA
Year:
2007
Document type:
Article
Affiliation country:
United States